Skip to main content
OpenTrials
Completed

NCT Number: NCT04218110

Preoperative Skin Preparation Study to Evaluate the Antimicrobial Capabilities of Four Test Substances

Comparative study of antimicrobial effectiveness evaluation of of 26ml Project X, 10.5ml Project X, 5.1ml Project X and Prevantics Maxi swabstick following ASTM E1173 - Standard test method for evaluation of preoperative, precatheterization or preinjection skin preparations.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Eurofins EVIC

Bucharest, 040256, Romania

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female at least 18 years of age and of any race
  • In good general health
  • Read, understand and sign the Informed Consent Form (ICF)
  • If female of child-bearing potential, are willing to use an acceptable method of contraception to prevent pregnancy (i.e. oral contraceptive, intra-uterine device, diaphragm, condom, abstinence, bilateral tubal ligation, or are in a monogamous relationship with a partner who has had a vasectomy)
  • Female subjects of child-bearing potential, must have a negative Urine Pregnancy Test (UPT) on Treatment Day prior to any applications of the study products

Exclusion criteria

  • Exposure of test sites to antimicrobial agents, medicated soaps, medicated shampoos, or medicated lotions, use of biocide-treated pools or hot tubs, use of tanning beds, or sunbathing during the 14-day washout conditioning period and during the test period
  • Exposure of the test sites to strong detergents, solvents, or other irritants during the 14-day washout conditioning period and during the test period
  • Wear fabric softener, bug repellent or UV-treated clothing during the 14-day washout conditioning period and during the test period
  • Receive an irritation score of 1 (any redness, swelling, rash, or dryness present at any treatment area) for any individual skin condition prior to the Treatment Day baseline sample collection
  • Use of systemic or topical antibiotic medications, steroid medications (other than for hormonal contraception or post-menopausal reasons), or any other product known to affect the normal microbial flora of the skin during the 14-day washout conditioning period and during the test period
  • Known allergies or sensitivities to vinyl, latex (rubber), alcohols, metals, inks, or tape adhesives, or to common antibacterial agents found in soaps, lotions, or ointments, particularly isopropyl alcohol or chlorhexidine gluconate
  • A medical diagnosis of a physical condition, such as a current or recent severe illness, asthma, diabetes, hepatitis, an organ transplant, mitral valve prolapses, congenital heart disease, internal prostheses, or any immunocompromised conditions such as AIDS (or HIV positive)
  • Pregnancy, plans to become pregnant within the washout and test periods of the study, or nursing a child
  • Any tattoos or scars within 2" (5.08 cm) of the test sites
  • Dermatoses, cuts, lesions, active skin rashes, or breaks or other skin disorders within 6" on or around the test sites
  • A currently active skin disease or inflammatory skin condition (for example, contact dermatitis) anywhere on the body that, in the opinion of the Consulting Physician or PI, would compromise subject safety or study integrity
  • Showering, bathing, or swimming within the 72-hour period prior to sampling for Treatment Day, and throughout the test period
  • Participation in another clinical study in the past 30 days or current participation in another clinical study at time of signing informed consent
  • Any medical condition or use of any medications that, in the opinion of the PI, should preclude participation
  • Unwillingness to fulfill the performance requirements of the study.

Treatment and study plan

Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic

Drug

Application of antiseptic drug to the inguinal area of the subjects

Other names: Project X 26ml

Prevantics 3.15 % / 70 % Swabstick

Drug

Application of antiseptic drug to the inguinal area of the subjects

Other names: Prevantics Maxi Swabstick

Primary outcomes

  1. Change in Bacterial Microflora in the Inguinal Area

    Time frame: 10 minutes

    Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention

Secondary outcomes

  1. Change in Bacterial Microflora in the Inguinal Area

    Time frame: 30 seconds

    Bacterial microflora (log10) will be measured via cup scrub method following the administration of the intervention

Sponsors and collaborators

Lead sponsor

Professional Disposables International, Inc.

Industry

Registry information

Official study title

Preoperative Skin Preparation Study Following ASTM E1173 Methods to Evaluate the Antimicrobial Capabilities of Four Test Substances

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jan 6, 2020
Registry last updated
Oct 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.